Invasive pneumococcal disease before, during and after the SARS-CoV-2 pandemic
Enfermedades infecciosas y microbiologia clinica (English ed.) · 2026
DOI: 10.1016/j.eimce.2025.503033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Enfermedades infecciosas y microbiologia clinica (English ed.), 2026. Verfasst von Irati Arregui García und 4 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Microbiología Clínica, Hospital Universitario de Navarra, Pamplona, Spain. Electronic address: irati.arregui@gmail.com. Hauptthemen laut MEDLINE: COVID-19, Pneumococcal Infections, Pandemics. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The aim of this study was to analyse the changes in the incidence of invasive pneumococcal disease (IPD) before, during, and after the SARS-CoV-2 pandemic. METHODS: Cases of IPD detected through active epidemiological surveillance in Navarre, Spain, from 2018 to 2024 were analysed. Incidence rates were compared across three periods: pre-pandemic (2018-2019), pandemic (2020-2022), and post-pandemic (2023-2024) overall and by age groups and serotypes RESULTS: From 2018 to 2024, a total of 437 IPD cases were diagnosed in Navarre. The incidence of IPD decreased from 11.6 to 5.6 cases per 100,000 persons during the pandemic period and return to 13.0 cases per 100,000 persons in the post-pandemic period. The incidence decreased across all age groups in both, serotypes included and not included in the 13-valent pneumococcal conjugate vaccine (PCV13). Serotype 3 was the most frequent in the three periods, representing 20.3% of all cases. In the post-pandemic period, 35.2% of cases were due to serotypes included in the PCV-13, 45.7% in the PCV-15 and 64.2% in the PCV-20. CONCLUSIONS: During the SARS-CoV-2 pandemic, the incidence of IPD decreased across all age groups for both, PCV13-included and not included serotypes. In the post-pandemic period, incidence returned to pre-pandemic levels. Whole-genome sequencing techniques helped to serotyping of S. pneumoniae, and thus, complemented epidemiological surveillance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio de Microbiología Clínica, Hospital Universitario de Navarra, Pamplona, Spain. Electronic address: irati.arregui@gmail.com.
- Servicio de Microbiología Clínica, Hospital Universitario de Navarra, Pamplona, Spain.
- Servicio de Microbiología Clínica, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas, Spain.
- Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain; Instituto de Salud Pública y Laboral de Navarra, Pamplona, Navarra, Spain; CIBER Epidemiología y Salud Pública, Madrid, Spain.
- Servicio de Microbiología Clínica, Hospital Universitario de Navarra, Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain; CIBER Epidemiología y Salud Pública, Madrid, Spain.
Zitieren
APA
Arregui García, I., Beguiristain, I., Fernández-Huerta, M., Castilla, J., & Portillo Bordonabe, M. E. (2026). Invasive pneumococcal disease before, during and after the SARS-CoV-2 pandemic. Enfermedades infecciosas y microbiologia clinica (English ed.). https://doi.org/10.1016/j.eimce.2025.503033
Vancouver
Arregui García I, Beguiristain I, Fernández-Huerta M, Castilla J, Portillo Bordonabe ME. Invasive pneumococcal disease before, during and after the SARS-CoV-2 pandemic. Enfermedades infecciosas y microbiologia clinica (English ed.). 2026. doi:10.1016/j.eimce.2025.503033
BibTeX
@article{ArreguiGarca2026,
author = {Arregui García, Irati and Beguiristain, Iñaki and Fernández-Huerta, Miguel and Castilla, Jesús and Portillo Bordonabe, María Eugenia},
title = {Invasive pneumococcal disease before, during and after the SARS-CoV-2 pandemic},
journal = {Enfermedades infecciosas y microbiologia clinica (English ed.)},
year = {2026},
doi = {10.1016/j.eimce.2025.503033}
}
EUVIMED